Eli Lilly and Company $LLY Shares Sold by Highland Capital Management LLC

Highland Capital Management LLC cut its stake in Eli Lilly and Company (NYSE:LLY) by 39.8% during the third quarter, HoldingsChannel reports. The institutional investor owned 4,756 shares of the company’s stock after selling 3,150 shares during the quarter. Highland Capital Management LLC’s holdings in Eli Lilly and Company were worth $3,629,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Sumitomo Mitsui Financial Group Inc. acquired a new stake in shares of Eli Lilly and Company in the second quarter worth approximately $27,000. Evolution Wealth Management Inc. purchased a new position in Eli Lilly and Company in the 2nd quarter valued at $29,000. Steph & Co. boosted its stake in Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after purchasing an additional 29 shares during the last quarter. Financial Gravity Companies Inc. purchased a new stake in shares of Eli Lilly and Company during the second quarter worth $31,000. Finally, Bare Financial Services Inc raised its position in shares of Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 29 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft boosted their target price on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Leerink Partners restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, December 18th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Eli Lilly and Company in a research report on Monday, December 22nd. Finally, Morgan Stanley upped their target price on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a report on Monday, November 24th. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,155.36.

Eli Lilly and Company Trading Up 0.0%

LLY opened at $1,077.26 on Friday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,111.99. The stock has a market capitalization of $1.02 trillion, a PE ratio of 52.70, a P/E/G ratio of 1.09 and a beta of 0.37. The business’s 50 day moving average price is $986.75 and its 200 day moving average price is $841.37. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter last year, the firm earned $1.18 earnings per share. The firm’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.